http://www.pharmalot.com/2008/12/what-oversightelan-board-angers-shareholders/ News, Comment and Conversation Fri, 10 Feb 2012 22:21:57 +0000 http://wordpress.org/?v=2.6.2 http://www.pharmalot.com/2008/12/what-oversightelan-board-angers-shareholders/#comment-384342 Barbara Thu, 11 Dec 2008 12:42:02 +0000 http://www.pharmalot.com/?p=18460#comment-384342 Kelly Martin had absolutely no experience as CEO and no background in biotechs. He was and still is the worst choice of a CEO. We shareholders have suffered greatly during his learning curve especially at his total mishandling of the ICAD meeting on July 29 where the Bapinuzimab PII results were presented. As someone who was heavily invested I suffered heavy financial losses. At the very least he should have seen that the presentation was during market hours or that trading was halted until the information was fully disclosed. The board should replace him and if not, maybe the board should be replaced. Kelly Martin had absolutely no experience as CEO and no background in biotechs. He was and still is the worst choice of a CEO. We shareholders have suffered greatly during his learning curve especially at his total mishandling of the ICAD meeting on July 29 where the Bapinuzimab PII results were presented.
As someone who was heavily invested I suffered heavy financial losses. At the very least he should have seen that the presentation was during market hours or that trading was halted until the information was fully disclosed.
The board should replace him and if not, maybe the board should be replaced.

]]>